24/7 Market News- Silexion Therapeutics Reports Positive SIL-204 Preclinical Studies Data

October 1, 2024

DENVER, Colo., Oct 01, 2024 (247marketnews.com)- Silexion Therapeutics (NASDAQ: SLXN) reported that SIL-204’s, its second-generation siRNA candidate, latest microparticle formulation can inhibit the growth and induce necrosis of the human pancreatic cell line that bears the KRAS G12D mutation, the largest segment of pancreatic cancer subtypes, xenotransplanted into mice.

SIL-204 demonstrated considerable tumor reduction in the human pancreatic tumor cell lines with the KRAS G12D (Panc -1) mutations by combining oncogene silencing with siRNA.

The PLGA depot rods to PLGA microparticles (MPs) transition resulted in a superior extended-release profile and enhanced the therapeutic potential.

Silexion plans to initiate the SIL-204 toxicology studies in the upcoming months and move SIL-204 into Phase 2/3 clinical trials in the first half of 2026.

Silexion’s Chairman and CEO, Ilan Hadar, commented, “These optimizations represent a significant step forward in our development of SIL-204.

“The improvements in cellular uptake and the enhanced extended-release formulation further strengthen our confidence in SIL-204’s potential. We look forward to commencing our next set of studies in preparation for our Phase 2/3 clinical trial.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.